Executive Management Team
Chief Executive Officer
Mr. Heydler was President and CEO at Barcelona Design Inc. based in San Jose, USA. Before joining Barcelona, Mr. Heydler served as President and CEO for InterPro Business Solutions, Inc., USA. He was Vice President and Executive Officer at Documentum Inc., a leading software and solutions provider with specific focus on the pharmaceutical and life sciences industry.
He built and drove Documentum’s European operations and assumed worldwide responsibility for Marketing and Documentum’s Application Business subsequently. Prior to this engagement, he served as Vice President and General Manager Europe for Cadence Design Systems and held senior leadership positions at Siemens AG.
Mr. Heydler holds a Diplom-Ingenieur degree in Electric Engineering and Computer Science from the Technical University in Munich.
Chief Operating Officer
Prior to joining Definiens, Mr. Neeleman was the COO Product Group Lithography Applications for ASML. He also was responsible for the global X-Ray Systems Business and the Components Business of Philips Healthcare for 8 years. During his tenure at ASML and Philips Healthcare, Mr. Neeleman transformed businesses towards profitable growth, focusing on new markets, new technologies, efficiency, and teamwork. Mr. Neeleman has also held management roles in Philips’ mobile display businesses, and prior to that in Mettler Toledo.
In his role as Chief Operating Officer, Mr. Neeleman is responsible for leadership of research, development and professional services activities.
Mr. Neeleman has an MSc degree in Micro Mechanical Engineering from the Technical University Delft and an MBA from INSEAD.
Chief Financial Officer
Markus Rinecker, MD
Prior to joining Definiens, Dr. Rinecker served as Managing Director at one of the leading surgical hospitals in Munich. While managing 350 employees with full P&L responsibility, he established a new department for open heart surgery and streamlined organizational processes to increase the organization’s profitabiligy. For the hospital chain Humaine Kliniken GmbH he evaluated potential acquisition targets and participated in multiple share deal transactions. He was also actively involved in the start-up venture ProHealth AG, which opened Europe’s first full clinical proton radiation center for cancer therapy, in March 2009.
Dr. Rinecker holds a Doctoral Degree in Medicine at the Ludwig-Maximilians-University in Munich as well as a Masters Degree in Business Administration of INSEAD, France and Singapore.
Chief Medical Officer
Ralf Huss, MD
Prior to joining Definiens, Dr. Huss served as Global Head of Histopathology and Tissue Biomarkers at Roche Diagnostics, where he was involved in identifying new tissue biomarkers to stratify cancer patients as part of a global Personalized Healthcare strategy. Dr. Huss also co-founded the biotech company APCETH. He has training and experience in immunology, transplantation biology and stem cell research, has published more than 100 papers, and has worked with the Nobel Laureates Rolf Zinkernagel and E. Donnell Thomas.
In his role as Chief Medical Officer, Dr. Huss plays a key role in expanding Definiens’ image and data analysis into Tissue Diagnostics and Clinical Digital Pathology.
Dr. Huss holds global academic appointments at the Ludwig-Maximilians-University, Munich and the Wake Forest Institute for Regenerative Medicine, USA. He is also a Professor of Systems Biology at the University College Dublin.
Executive Vice President, Predictive Tests
Thomas Nifong, MD
Prior to joining Definiens, Dr. Nifong was Senior Vice President of Clinical Operations for Metamark Genetics, where he successfully led efforts to translate quantitative multiplex immunofluorescence research protocols into robust, reproducible laboratory developed tests (LDTs) for clinical use. He spent 10 years as a faculty member at the Penn State Hershey Medical Center where he gained extensive experience in molecular pathology, clinical laboratory medicine, and laboratory validation and management.
In his role as Executive Vice President of Predictic Tests, Dr. Nifong is responsible for regulated product development and commercialization for all clinical diagnostic projects incorporating Definiens technology. Dr. Nifong holds a BS in Chemical Engineering from Purdue University and an MD from the University of Rochester. He completed his residency training in Clinical Pathology and is a Diplomat of the American Board of Pathology and a Fellow of the American Society for Clinical Pathology and the College of American Pathologists.
Global Head of Sales and Business Development
He joined Definiens from AYOXXA Biosystems where he was Corporate Vice President of Global Commercial Operations. Prior to that he was Corporate Vice President of Global Marketing and Business Development for Dako (now Agilent Technologies). During his career he has held leadership positions with Roche and Bayer Diagnostics in Europe, the US, and Latin America across 9 different countries. Michael Rasche is excellent at building and mobilizing high-performing international teams who view it as their mission to deliver business critical projects. In his role as Global Head of Sales and Business Development, Mr. Rasche is responsible for continuing the momentum of Definiens driving sales in the strategic expansion from Research into the Clinical Development and Diagnostics Space.
Scientific Advisory Board
Scientific Advisory Board
Dr. Gerd Binnig founded Definiens with the goal to transform the image analysis industry by enabling more data to be extracted for better decisions. Dr. Binnig, along with his colleague Dr. Heinrich Rohrer, was awarded the Nobel Prize for Physics in 1986.
Manfred Dietel, MD
Dr. Manfred Dietel is Director, Institute of Pathology, Campus Charitè-Mitte. He is also a Member of the Board of Directors of the Association of German University Hospitals and a Member of the Board of Directors of the German Society of Pathology.
James L. Gulley, MD, PhD, F.A.C.P.
Dr. Gulley is Director of the Medical Oncology Service, Chief of the Genitourinary Malignancies Branch and Head of the Immunotherapy Section at NCI. He is an internationally recognized expert in cancer immunotherapy with a strong interest in prostate cancer. He serves as the principal investigator on several international clinical trials, among which for a prostate cancer vaccine and several trials using immune checkpoint inhibitors.
David Harrison, MD
David Harrison is Professor of Pathology, and Director of Research, in the School of Medicine, University of St Andrews, Scotland. He holds honorary positions in Universities of Edinburgh and Florida. He is also Director of Development for Laboratory Medicine for the Edinburgh University Hospitals. He chairs the UK government Committee on Carcinogenicity.
Ronald Herbst, PhD
Dr. Ronald Herbst is Vice President of Research and Development and Head of Oncology Research for MedImmune. In this role, Ronald is responsible for the overall oncology research strategy and pre-clinical development of novel drug candidates. Ronald joined MedImmune in February, 2006 as associate director of oncology research. Prior to MedImmune Ronald was Senior Principal Investigator in the Oncology Department at Schering-Plough Biopharma (formerly DNAX).
Dirk Jäger, MD
Dr. Jäger is the Director Medical Oncology, National Center for Tumor Diseases and University Medical Center Heidelberg.
Walter Kolch, MD, FRSE, MRIA
Walter Kolch is Director of Systems Biology Ireland, which was rated amongst the top 5 Systems Biology Institutes worldwide focussing on human disease in 2014.
Holger Moch, MD
Dr. Holger Moch is the Director, Medical Division Pathology and Laboratory Medicine at University Hospital in Zurich, Switzerland. He is also a Full Professor of Pathology at the University of Zurich and Chairman, Institute for Pathology, University Hospital Zurich, Switzerland.